Ofatumumab patent expiry?

Ofatumumab (brand examples: Arzerra for CLL; Kesimpta for multiple sclerosis) is patented in multiple jurisdictions, and the “patent expiry” depends on which patent family and what country you mean.

Here’s the practical way to think about it:

• Kesimpta (ofatumumab for MS): Ofatumumab’s key originator patent protections in the US and EU have generally been expected to run into the 2020s, but exact expiry dates vary by patent number, territory, and any patent-term extensions/supplementary protection (SPCs).
• Arzerra (ofatumumab for CLL): The CLL indication and manufacturing/ formulation/process patents are often protected by additional, separate patent families, so expiry can differ from MS.

What I need from you to give a precise date

1. Which indication: MS (Kesimpta) or CLL (Arzerra)?
2. Which country/region: US, EU/UK, Canada, etc.
3. If you have it: patent number(s) or the company/assignee you’re tracking.

If you tell me the country + indication, I can narrow it to the relevant patent family and the most likely earliest expiry / exclusivity end date (including whether there were delays like SPCs, pediatric extensions, or similar provisions).